These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 6233994)

  • 41. The new drug evaluation process: risk benefit ratio.
    Somberg JC
    Am J Ther; 2005; 12(3):199-200. PubMed ID: 15891261
    [No Abstract]   [Full Text] [Related]  

  • 42. Post-marketing surveillance of licensed medicinal and other products.
    Griffin JP
    Health Trends; 1981 Aug; 13(3):85-8. PubMed ID: 10258571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. From the pen to the patient: minimising medication errors.
    Mehta S; Gogtay NJ
    J Postgrad Med; 2005; 51(1):3-4. PubMed ID: 15793329
    [No Abstract]   [Full Text] [Related]  

  • 44. Be careful when you prescribe these drugs.
    Teplitsky B
    Med Times; 1973 Mar; 101(3):55-7. PubMed ID: 4687939
    [No Abstract]   [Full Text] [Related]  

  • 45. Towards the reduction of medication errors in orthopedics and spinal surgery: outcomes using a pharmacist-led approach.
    Weiner BK; Venarske J; Yu M; Mathis K
    Spine (Phila Pa 1976); 2008 Jan; 33(1):104-7. PubMed ID: 18165755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Adverse reactions to drugs and drug surveillance].
    Laporte JR
    Med Clin (Barc); 1989 Apr; 92(14):536-8. PubMed ID: 2666766
    [No Abstract]   [Full Text] [Related]  

  • 47. Reporting of adverse drug and biologic reactions in Mississippi hospitals.
    Fincham JE; Brown TR; Garner DD
    Hosp Pharm; 1988 Mar; 23(3):248-51. PubMed ID: 10286840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postmarketing drug surveillance: are our priorities right?
    Fries JF
    J Rheumatol; 1988 Mar; 15(3):389-90. PubMed ID: 3379617
    [No Abstract]   [Full Text] [Related]  

  • 49. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G; Vincens M; Castot A
    Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
    [No Abstract]   [Full Text] [Related]  

  • 50. Preventing medication errors. AMA asks physician assistance.
    J Fla Med Assoc; 1995 Jul; 82(7):476-7. PubMed ID: 7673883
    [No Abstract]   [Full Text] [Related]  

  • 51. Postmarketing drug dosage changes.
    Peck CC
    Pharmacoepidemiol Drug Saf; 2003; 12(5):425-6. PubMed ID: 12899120
    [No Abstract]   [Full Text] [Related]  

  • 52. Adverse drug reaction reporting system: developing a well-monitored program.
    Kilarski DJ; Ziegler B; Coarse J; Buchanan C
    Hosp Formul; 1986 Sep; 21(9):949-52. PubMed ID: 10289704
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Poly-medication and drug interaction in geriatrics].
    Sternon J; Gilles C
    Rev Med Brux; 1996 Dec; 17(6):389-96. PubMed ID: 9045270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Iatrogenic diseases linked to the use of drugs and common medical equipment].
    Carpentier F
    Rev Prat; 2001 Apr; 51(7):769-73. PubMed ID: 11387675
    [No Abstract]   [Full Text] [Related]  

  • 55. What drugs are our frail elderly patients taking? Do drugs they take or fail to take put them at increased risk of interactions and inappropriate medication use?
    Frank C; Godwin M; Verma S; Kelly A; Birenbaum A; Seguin R; Anderson J
    Can Fam Physician; 2001 Jun; 47():1198-204. PubMed ID: 11421047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Premier databases to support FDA surveillance related to drug safety.
    Health Care Strateg Manage; 2001 Nov; 19(11):10. PubMed ID: 11729600
    [No Abstract]   [Full Text] [Related]  

  • 57. Therapeutic auditing at the national and international level.
    Westerholm B
    Br J Clin Pharmacol; 1986; 22 Suppl 1(Suppl 1):55S-59S. PubMed ID: 3567033
    [No Abstract]   [Full Text] [Related]  

  • 58. Postmarketing studies of drug efficacy.
    Strom BL; Melmon KL; Miettinen OS
    Arch Intern Med; 1985 Oct; 145(10):1791-4. PubMed ID: 3899034
    [No Abstract]   [Full Text] [Related]  

  • 59. Post-marketing studies of drug efficacy: why?
    Strom BL; Melmon KL; Miettinen OS
    Am J Med; 1985 Mar; 78(3):475-80. PubMed ID: 3976706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug surveillance in Spain.
    Alloza JL
    Arch Farmacol Toxicol; 1985 Aug; 11(2):141-2. PubMed ID: 4083922
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.